A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Stopped Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by Sponsor.

Conditions

• Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)
• Ph+ Mixed Phenotype Acute Leukemia (MPAL)
• Philadelphia Chromosome-Like ALL (Ph-like ALL)

Interventions

• DRUG: Ponatinib
• DRUG: Chemotherapy Agents

Sponsor

Takeda